Wedbush Predicts Weaker Earnings for Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Equities research analysts at Wedbush reduced their Q2 2025 earnings per share (EPS) estimates for shares of Kiniksa Pharmaceuticals in a report issued on Tuesday, April 29th. Wedbush analyst D. Nierengarten now forecasts that the company will earn $0.24 per share for the quarter, down from their prior forecast of $0.38. Wedbush has a "Outperform" rating and a $34.00 price objective on the stock. The consensus estimate for Kiniksa Pharmaceuticals' current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals' Q3 2025 earnings at $0.25 EPS, Q4 2025 earnings at $0.28 EPS, FY2025 earnings at $0.89 EPS, FY2026 earnings at $1.48 EPS, FY2027 earnings at $1.98 EPS and FY2028 earnings at $2.31 EPS.

KNSA has been the topic of a number of other reports. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 price objective on the stock. Jefferies Financial Group upped their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $38.80.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ:KNSA traded down $0.09 during trading hours on Friday, hitting $27.65. The stock had a trading volume of 662,184 shares, compared to its average volume of 478,684. The stock's fifty day simple moving average is $21.77 and its 200 day simple moving average is $21.29. The firm has a market capitalization of $2.01 billion, a price-to-earnings ratio of -197.49 and a beta of 0.31. Kiniksa Pharmaceuticals has a 1-year low of $17.38 and a 1-year high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.09. The business had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business's revenue was up 72.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.25) EPS.

Insider Transactions at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 8,879 shares of Kiniksa Pharmaceuticals stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $23.10, for a total transaction of $205,104.90. Following the sale, the chief financial officer now owns 23,382 shares in the company, valued at $540,124.20. The trade was a 27.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Ross Moat sold 64,035 shares of the company's stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $25.21, for a total transaction of $1,614,322.35. Following the completion of the sale, the insider now directly owns 9,415 shares in the company, valued at approximately $237,352.15. The trade was a 87.18 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 218,548 shares of company stock worth $5,210,745. 54.57% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Braidwell LP increased its stake in shares of Kiniksa Pharmaceuticals by 19.3% in the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company's stock valued at $68,289,000 after buying an additional 557,934 shares during the period. JPMorgan Chase & Co. boosted its holdings in Kiniksa Pharmaceuticals by 138.9% in the fourth quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company's stock valued at $9,451,000 after acquiring an additional 277,827 shares during the last quarter. Millennium Management LLC increased its position in Kiniksa Pharmaceuticals by 50.9% in the fourth quarter. Millennium Management LLC now owns 779,672 shares of the company's stock worth $15,422,000 after purchasing an additional 263,146 shares during the period. Raymond James Financial Inc. acquired a new stake in Kiniksa Pharmaceuticals in the fourth quarter worth about $3,955,000. Finally, Hudson Bay Capital Management LP raised its holdings in Kiniksa Pharmaceuticals by 150.0% during the 4th quarter. Hudson Bay Capital Management LP now owns 225,000 shares of the company's stock worth $4,450,000 after purchasing an additional 135,000 shares during the last quarter. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.